Abstract
The serum expression of a novel tumour marker, CA 242, defined by monoclonal antibody C 242, was studied in 179 patients with pancreatic cancer. The results were compared with CA 19-9, CA 50 and CEA. CA 242 is a carbohydrate closely related, but not identical, to CA 19-9 and CA 50. The overall sensitivity of the CA 242 assay was 74%: 55% in stage I, 83% in stage II-III and 78% in stage IV disease. The specificity calculated from 112 patients with benign diseases was 91%. CA 19-9 had a higher sensitivity of 83%, but the specificity was only 81%. When comparing the markers by receiver operating characteristic analysis, the sensitivities were almost identical at all specificity levels. The CA 242 level was elevated in 7%, 15% and 7% of patients with benign pancreatic, biliary and liver disease respectively. The corresponding figures for CA 19-9 were 19%, 28% and 15% respectively. The sensitivity of CA 242 was higher than that of CA 50 and CEA at all specificity levels. In conclusion, tumour marker CA 242 seems to be a useful diagnostic tool for the diagnosis of pancreatic cancer, and is an alternative to CA 19-9. The advantage of CA 242 over CA 19-9 is its higher specificity when using the recommended cut-off levels of the assays.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Haglund, C., Lundin, J., Kuusela, P. et al. CA 242, a new tumour marker for pancreatic cancer: a comparison with CA 19-9, CA 50 and CEA. Br J Cancer 70, 487–492 (1994). https://doi.org/10.1038/bjc.1994.332
Issue Date:
DOI: https://doi.org/10.1038/bjc.1994.332
This article is cited by
-
Identification of cystatin SN as a novel biomarker for pancreatic cancer
Tumor Biology (2015)
-
CA19-9 and CA242 as tumor markers for the diagnosis of pancreatic cancer: a meta-analysis
Clinical and Experimental Medicine (2014)
-
Serum carbohydrate antigen 242 expression exerts crucial function in the diagnosis of pancreatic cancer
Tumor Biology (2014)
-
Diagnostic value of serum carbohydrate antigen 19-9 in pancreatic cancer: a meta-analysis
Tumor Biology (2014)
-
Evaluation of CA 242 as a Tumor Marker in Gallbladder Cancer
Journal of Gastrointestinal Cancer (2012)